KRAS mutation-driven O-GlcNAcylation of CLDN18.2 enhances the progression of pancreatic cancer and reduces the efficacy of CLDN18.2-targeted therapy

Journal:

Gut

Published:

2026-01-09

DOI:

10.1136/gutjnl-2025-336277

Affiliations:

10

Authors:

16

Go to article

Institutions	Authors	Share
Tianjin Medical University Cancer Institute and Hospital, TMU, China	10.066667 10.066667	0.63
State Key Laboratory of Druggability Evaluation and Systematic Translational Medicine, China	4.283333	0.27
State Key Laboratory for Structural Chemistry of Unstable and Stable Species, China	1.000000	0.06
Fudan University Shanghai Cancer Center (FUSCC), China	0.250000	0.02
Zhejiang Cancer Hospital (ZJCH), China	0.200000	0.01
Hangzhou Institute of Medicine (HIM), CAS, China	0.200000	0.01

Interested in Oncology and Carcinogenesis?